A Phase 2b Randomized, Double-blind, Placebo-controlled, Multicenter, Dose-ranging Study To Evaluate The Efficacy And Safety Profile Of Pf-06651600 With A Partially Blinded Extension Period To Evaluate The Efficacy And Safety Of Pf-06651600 And Pf-06700841 In Subjects With Active Non-segmental Vitiligo
Phase of Trial: Phase II
Latest Information Update: 21 Feb 2019
At a glance
- Drugs PF 6651600 (Primary) ; PF 6700841 (Primary)
- Indications Vitiligo
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 08 Jan 2019 Planned End Date changed from 7 Dec 2020 to 17 Mar 2021.
- 08 Jan 2019 Planned primary completion date changed from 15 Jun 2020 to 23 Sep 2020.
- 10 Dec 2018 Planned End Date changed from 21 Oct 2020 to 7 Dec 2020.